TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-70 years~* increased risk for infections - at least 4 cold episodes within 12 months~* commitment to adhere to their accustomed diet and physical activity~* women of child-bearing potential have to agree to use appropriate birth control methods~* written consent of the subject to participate is a prerequisite for study participation~Exclusion Criteria:~* acute / chronic upper airways disease~* chronic cough of any origin~* acute / chronic lower airways disease~* any allergic reaction that may influence the study outcome (e.g. acute/chronic rhinitis)~* history of nasal reconstructive surgery~* presence of nasal ulcers or nasal polyps~* severe nasal septum deviation or other condition that could cause nasal obstruction~* congenital or acquired immunodeficiency disease (e.g. HIV infection)~* severe organ or systemic diseases~* body temperature above 37.5°C~* suspected swine flu or influenza~* vaccination against influenza or swine flu within 3 months prior to study start~* stomach/gastrointestinal diseases~* sleep disorder~* psychiatric disorders~* known sensitivity to the ingredients of the investigational product~* intake of products that may influence the study outcome within the last 14 days prior to study start and during the study~* analgesics , antibiotics or decongestant nose drops/spray, unless they are used as rescue medications~* pregnancy or nursing~* alcohol / drug abuse~* simultaneous participation in another clinical trial or participation in a clinical trial within the last 30 days~* insufficient compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- IQP-AS-105 (Type: ACTIVE_COMPARATOR): One tablet daily
- Placebo (Type: PLACEBO_COMPARATOR): One tablet daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 85 years~* Fisher score 2-4~* recruitment within 12 - 72 hours of hemorrhage~Exclusion Criteria:~* pregnancy~* breast feeding~* allergy to donepezil or other piperidine derivatives~* participants unwilling to use appropriate birth control up to 6 weeks after enrolment~* known dementia~* severe liver failure (Child-Pugh C)~* sick sinus syndrome or other supraventricular cardiac conduction abnormalities~* inspired oxygen requirement greater than 60%~* history of brittle asthma or obstructive airway disease~* aneurysm unsuitable for endovascular coiling~* concomitant use of cholinesterase inhibitor (e.g. rivastigmine, galantamine, etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: ACTIVE_COMPARATOR): Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
- Control (Type: NO_INTERVENTION): Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older with diabetic macular edema (DME) diagnosis secondary to diabetes mellitus Type 1 or 2~* Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 23 in the study eye~* Willing and able to comply with clinic visits and study-related procedures~* Provide signed inform consent~Exclusion Criteria:~* Any signs of high risk proliferative diabetic retinopathy in the study~* Previously-treated patients who are not responders to anti-VEGF~* Panretinal laser photocoagulation within 6 months and macular laser photocoagulation with 3 months of screening in the study eye~Note: Other inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): AXT107 0.1 mg/eye
- Mid Dose (Type: EXPERIMENTAL): AXT107 0.25 mg/eye
- High Dose (Type: EXPERIMENTAL): AXT107 0.5 mg/eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Stricture Definition and Treatment (STRIDENT) Observational Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inflammatory bowel disease patients with intestinal stricture(s) identified on CT, MRI or endoscopy but without associated symptoms~Exclusion Criteria:~* Low rectal or anal strictures~* Evidence of dysplasia or malignancy from stricture biopsies or adjacent mucosal biopsies~* Patients for whom endoscopy is not suitable due to co-morbidities or clinical state~* Inability to give informed consent~* Suspected perforation of the gastrointestinal tract~* Inability to undergo MRI small bowel due to a contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Femoral & Lateral Femoral Cutaneous Nerve Blocks for THA Acute Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 year old,~* ASA physical status classification system score (ASA) \<=3~* due to undergo elective unilateral hip arthroscopy by one surgeon Dr. Nho (Co-Principal Investigator)~Exclusion Criteria:~* ASA physical status classification system score) (ASA) \>3~* history of opioid dependence or abuse~* current chronic analgesic therapy (daily use =\>20 mg oxycodone-equivalent opioid use within 2 weeks before surgery and duration of use \>=4 weeks)~* allergy to study medications (fentanyl and ropivicaine)~* any neuromuscular deficit of the ipsilateral femoral nerve or quadriceps femoris muscle (including diabetic peripheral neuropathy)~* diagnosis of hypertension and/or current treatment for hypertension~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grp 1 Ropivacaine Block (Type: ACTIVE_COMPARATOR): Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
- Grp 2 Placebo Block (Type: PLACEBO_COMPARATOR): Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with haematological malignancies such as~  * any acute myeloid leukemia (AML) beyond Complete Remission (CR) 1~ * any acute lymphoblastic leukemia (ALL) beyond CR1~ * multiple myeloma (MM) at any relapse/progression, except refractory disease~ * MM with unfavourable cytogenetic profile at diagnosis~ * MM with less than a partial response (PR) after induction therapy~* Karnofsky Index ≥ 80 %~* Adequate contraception in female patients of child-bearing potential.~* Written informed consent~* Availability of one of the following:~  * A matched related or unrelated donor (MRD or MUD)~Exclusion Criteria:~* A hematopoietic cell transplantation-specific comorbidity index \> 4~* Active non-controlled infectious disease at the moment of inclusion~* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection~* Impaired liver function (Bilirubin \> 2.0 x upper normal limit; Transaminases \> 3.0 x upper normal limit)~* Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~* Pleural effusion or ascites \> 1.0 L~* Pregnancy or lactation~* Known hypersensitivity to treosulfan and/or fludarabine and/or rapamycin~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent~* Previous spinal cord radiotherapy with dose ≥ 45 Gy equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Treatment (Type: EXPERIMENTAL): Conditioning treatment Treosulfan+TMI; SCT; GvHD prophylaxis;

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years~* GI symptoms for at least 2 months before entering study~Exclusion Criteria:~* Very high body weight~* Significant diarrhea~* Ulcers~Symptom severity score collected via diary Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotics on Sputum Inflammation and Pulmonary Infections in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* cystic fibrosis mild to moderate~* at least 3 pulmonary exacerbations requiring antibiotics per year~* Pseudomonas aeruginosa in the sputum~* able to produce sputum~Exclusion Criteria:~* severe pulmonary disease~* less than 3 pulmonary exacerbations per year~* unable to produce sputum

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics, Treatment, Food Additive (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes who have been on metformin for the last 6 months and are taking a stable dose of metformin (≥ 1500 mg/d) as monotherapy for at least the last 3 months~* Male or female, 18-70 years of age~* All female patients must be surgically sterile or post-menopausal (at least 40 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two medically accepted methods of contraception including a barrier method. Depo contraceptives are excluded.~* Female patients must not be pregnant or lactating~* BMI ≥ 26 (patients of Asian Indian origin ≥ 22) kg/m2~* HbA1c ≥ 7.5%, ≤ 10.5%~* FPG ≥ 120 mg/dL, ≤ 240 mg/dL~Exclusion Criteria:~* History of diabetes secondary to pancreatitis or pancreatectomy~* Any history of ketoacidosis~* History of insulin use within last one year (insulin use while hospitalized is acceptable)~* Weight loss \> 10 pounds in the three months prior to screening visit~* History of TZD use (Actos® or Avandia®) within 6 months of screening visit~* History of TZD discontinuation due to side effect or lack of efficacy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MBX-102 400 (Type: EXPERIMENTAL): None
- MBX-102 600 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Actos (Type: ACTIVE_COMPARATOR): 30-45 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Improving Knowledge in Heart Failure Inpatient With Therapeutic Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization in the Department of General Internal Medicine or Cardiology for decompensated heart failure with lowered left ventricular ejection fraction (LVEF) (≤40%) from any cause or mildly lowered LVEF (41-49%) with the presence of heart failure-specific drug therapy~* Stability of the patient's clinical condition~* ≥ 2 heart failure medications~* ≥18 years~* Full capacity of discernment~* Absence of cognitive impairment~* Ability to speak, understand and read in French~* Get a personal telephone~* Consent form signed by the participant~Exclusion Criteria:~* Inability to follow study procedures~* Institutionalized persons~* Asylum seekers, homeless people, prisoners~* Incapacity of judgment and discernment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient therapeutic education group (Type: EXPERIMENTAL): The intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)
- Usual hospital care group (Type: NO_INTERVENTION): The control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 or above.~* Endoscopically removed colorectal lesion with the following pathological characteristics:~  * A moderately-to-well differentiated adenocarcinoma.~ * If possible to judge: distance between adenocarcinoma and vertical or lateral resection margin is less than 1 mm.~ * In case of piecemeal resection: unjudgeable radicality (mostly due to loss of orientation and multiple fragments).~ * Absence of / unjudgeable lymphatic / vascular invasion.~ * No or only grade I tumor budding.~* No suspicion of dissemination on the following investigations: serum carcino-embryonic antigen, a computer tomographic (CT) scan of the abdomen and a chest X-ray; in case of a rectal tumor (less than 15 cm from the anal verge): an additional magnetic resonance imaging of the rectum.~* Operation is advised in agreement with the Dutch Guideline on Colorectal cancer, planned and agreed on by the patient.~* Written informed consent is obtained.~Exclusion Criteria:~* Pathology shows one or more of the following characteristics:~  * A radical en-bloc resection with a free vertical and lateral margin of ≧ 1 mm.~ * A poorly differentiated or signet-cell containing adenocarcinoma.~ * Lymphatic or vascular invasion (if this feature is unjudgeable due to piecemeal resection, no exclusion is done).~ * Tumor budding grade II-III.~* Suspicion of dissemination on investigations as mentioned in the inclusion criteria.~* Patients already receiving anti-tumor treatment for another tumor or a synchronic colorectal cancer.~* Patients in whom a second-look endoscopy would require major and unacceptable effort and / or resources, for instance clinical admission for bowel preparation, long travel, general anesthesia, extremely difficult to reach polypectomy site. Such at the decision of the patient and / or treating physician.~* Patient is planned for trans-anal surgery.~* Patient is not planned for surgery.~* Patient is pregnant.~* Patient does not provide written informed consent or is unable to provide such.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flexible sigmoidoscopy or colonoscopy (Type: OTHER): Subjects will undergo these investigation to take biopsies from the polypectomy scar.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between 12 and 18 years of age who are admitted to the hospital for an acute vaso-occlusive crisis~* Patients must require a demand PCA and able to tolerate oral pain medications~Exclusion Criteria:~* - Requires a continuous PCA~* Unwilling to be compliant with the assigned arm of study (e.g. Non-compliance with sleep or visiting regimen, or questionnaires)~* Non-English speaking child or parent (questionnaires not available/validated in another language)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
- Comprehensive Care Plan (Type: EXPERIMENTAL): Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Management of Malignant Dysphagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Confirmed esophageal/gastroesophageal (GEJ) cancer (Siewert Type I and Type II only) of any histology on biopsy~* Dysphagia score ≥2~* Stage IV cancer/Metastatic disease~Exclusion Criteria:~* Expected life expectancy \< 3 months~* Inability to undergo stent insertion~* Siewert Type III gastroesophageal cancer~* Esophageal-Airway fistula

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Self-expanding stent alone (Type: ACTIVE_COMPARATOR): All patients in Arm A will receive self-expanding stent alone
- Brachytherapy and Stent therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues